EPHA3 and central nervous system cancer: Therefore, the EphA3 antibody (anti-EphA3) as a non-fucosylated IgG1j (human f-allotype) monoclonal antibody with low toxicity can further enhance glioma targeting via its specific interactions with the EphA3 receptor.